PATENT CLAIM ANALYSIS

Application Number: 16038735
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["514", "176000"]

Abstract:
Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.

Claim (Index 45):
The method of  claim 41 , wherein the cytotoxic compound has the structure (IV): where R 5  is a heterocycle.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 95.0
- Lexical Diversity: 1.17857
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15077099', '12995669', '15923668', '14678905', '15419642']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7270438612106691
- 35 USC 102 Novelty (BERT): 0.560967985134105
- Combined Prediction Score: 0.7104362736030128
- Mean Citation Score: 263.773224
- Max Citation Score: 442.86853
- Similarity Product: 286.98865437369165

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test